Supplement to "The role of pharmacologic management in neovascular age-related macular degeneration : Role of pharmacologic management in neovascular age-related macular degeneration : clinical and cost-effectiveness

Technologies in Health (CADTH) 3. What would the incremental cost- commissioned a study of the clinical efficacy effectiveness of ranibizumab be compared and cost-effectiveness of the management of to “watchful waiting” (i.e., no treatment) people with neovascular age-related macular for treatment of people with macular degeneration (AMD).1 The economic findings of degeneration? [...] If: The three arguments enclosed indicate (in order) the desired condition, the true value (1 in the model), and the false value (0 in the model). [...] Patients were 140 patients in the 0.5 mg-arm experienced seen in follow-up at three, six, nine, and 12 ocular inflammation, while 50 out of 239 months with the total percentage of patients patients in the 0.5 mg-arm of the MARINA trial remaining in the verteporfin arm and the experienced ocular inflammation. [...] The expert Once the annual number of treatments was panel also stated that the progression of CNV determined, the annual cost of PDT treatments leakage would need to be followed by both FA was calculated assuming the need for two IOP and OCT, and divided the number of tests checks with each treatment, four FAs, and eight equally between the two modalities.